Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Operating Cash Flow: $19,144M in FY2025, up 8.7% from a year earlier. That is the highest of the 11 years on record here.
Latest, FY2025
19,144
Period ended Dec 31, 2025
Change on a year earlier
+8.7%
17,619 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗
Reported in Financial statements + Form 6-K (reported directly for each 3-month quarter).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Operating Cash Flow ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19,144 | +8.7% | Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 17,619 | +21.9% | Novartis 20-F (0001370368-25-000004, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 14,458 | +1.6% | Novartis 20-F (0001370368-24-000004, filed 2024-01-31) ↗ |
| FY2022 | Dec 31, 2022 | 14,236 | -5.5% | Novartis 20-F (0001370368-23-000006, filed 2023-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 15,071 | +10.4% | Novartis 20-F (0001370368-22-000010, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 13,650 | +0.2% | Novartis 20-F (0001370368-21-000006, filed 2021-01-26) ↗ |
| FY2019 | Dec 31, 2019 | 13,625 | -4.5% | Novartis 20-F (0001370368-20-000003, filed 2020-01-29) ↗ |
| FY2018 | Dec 31, 2018 | 14,272 | +13.1% | Novartis 20-F (0001370368-19-000002, filed 2019-01-30) ↗ |
| FY2017 | Dec 31, 2017 | 12,621 | +10.0% | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
| FY2016 | Dec 31, 2016 | 11,475 | -3.5% | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
| FY2015 | Dec 31, 2015 | 11,897 | – | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
Breakdown
What makes up operating Cash Flow
- CapEx PPE-1,548 · FY2025
- CapEx Intangible Assets-2,352 · FY2025
- Capital Expenditure (annual)1,548 · FY2025
- Acquisitions-147 · FY2025
- Investing Cash Flow (annual)-4,877 · FY2025
- Financing Cash Flow (annual)-14,867 · FY2025
- Interest Paid-981 · FY2025
- Interest Received310 · FY2025
- Income Taxes Paid2,562 · FY2025
- Payments of Lease Liabilities-281 · FY2025
- Dividends Paid (annual)-7,818 · FY2025
- FX Effect (annual)576 · FY2025
- Net Change in Cash (annual)-24 · FY2025
Cite this data
StockData. (2026). Novartis Operating Cash Flow ($M), annual FY2015–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-cf-operating
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.